Gsk Plc ADR GSK

$50.75 -0.46 (-0.90%)

Valuation

Market cap
101,175,760,000
Revenue TTM
$43,077,970,000
Net income TTM
$7,537,690,000
PE ratio
10.64
Forward PE
10.59
Profit margin
17.50%
Debt to equity
1.06

Trading

Volume
3,160,303
Avg volume
4,085,850
Day's range
$50.29 – $50.92
Shares out
2,022,706,000
Stochastic %K
96%
Beta
0.33
Analysts
Sell
Price target
$59.40

Price

Company profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled...

Show more

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
44 20 8047 5000
Website
https://www.gsk.com
Address
79 New Oxford Street, London, United Kingdom

Latest news

Stocktwits

Maribor Oct 22, 8:22 PM
$GSK https://www.mediaite.com/media/news/breaking-lindsey-graham-paid-off-3-male-escorts-including-one-who-was-17-at-the-time-explosive-documentary-alleges
0 replies
JuggernautRaider Oct 22, 7:27 PM
$META $GSK $ALLR 😂 🇮🇳 💊 $AMGN 💩 🐕 wooooooof 🤮 😆
0 replies
Idfkytm Oct 22, 3:56 PM
$GSK
0 replies
BiotechSwings Oct 22, 2:57 PM
quiet clock on $GSK imo Nov 27 PDUFA, 36 days out, neladalkib in ALK positive lung cancer after a TKI Priority Review, Breakthrough and Orphan in hand, built to reach the brain and cover resistance mutations the older drugs miss trading 50.84 today, up 1.6 percent off a 50.02 close, and it came over in a 10.6 billion dollar deal for a reason ngl
0 replies
taxplanr Oct 22, 2:56 PM
DEFEATING THE BEAST SYSTEM BIOWEAPONS The beast system is going to be implemented whether we like it or not. We are not going to vote our way out of it. We may be able to vote our way out of mass migration but the plan is to inject every American with mRNA vaccines from $PFE $BNTX $MRNA and now $MRK and $GSK. The good news is ... it isn't hard to defeat this system. All these bioweapons run on lipid nano particles aka poly ethylene glycol. These systems disassemble with EDTA which should be taken with a charcoal binder. So if you are forced to take one of these to keep your job or enroll your child in school take them an hour before having to take any mRNA injection. And since so many people will be injected and they are designed to shed it would be wise to detox this way monthly. And since they are now using them on pets and farm animals it would be good to detox them also. Share on X and all your social media channels.
1 replies
Quantumup Oct 22, 10:15 AM
Jefferies⬆️ $IRON's PT to $149 from $128 and reiterated Buy $CUVL $GSK BMY INCY KROS Here's what Jefferies said in its note: We caught up w/ mgmt and discussed w/ investors post-Ph3 (+)/ best-in-disease topline from bito, first disease-modifying drug. We are increasingly bullish on Bito's commercial oppt'y w/~6-14K tangible pt pool for potential $1-2B opp'y. We see high POS for pot'l approval by mid'27 after NDA resubmission by YE26. Beyond Bito, IRON will provide data and reg updates for MF anemia program and longer data follow-up for PV program before YE26, likely at ASH'26.
0 replies
None_ Oct 21, 9:23 PM
$DTIL $GSK https://www.fiercebiotech.com/biotech/amid-bepirovirsen-triumph-gsk-quietly-scraps-trial-next-gen-hep-b-therapy
0 replies
tomonota Oct 21, 6:44 PM
https://stocktwits.com/news-articles/markets/equity/gsk-inovio-agios-sun-pharma-fda-decision-calendar-october/cZx8jI5RBML $GSK Inovio investors rallied shares to $14.74 on 3/31/2024 and the same value is likely to prevail on 10/30/26, reduced for shares issued, 4:1, but still 260% gains likely.
0 replies